Art. -Nr.: HY-B1110

Nomifensine

(Synonyms: (±)-Nomifensine; Nomifensin)

6 Cited Publications

Kundenbewertung

Based on 6 publication(s) in Google Scholar

Nomifensine ((±)-Nomifensine) is a potent norepinephrine (NE) and dopamine (DA) reuptake inhibitor. Nomifensine inhibits uptake of NE, DA and 5-HT in rat brain synaptosomes, with IC₅₀ values of 6.6 nM, 48 nM and 830 nM, and K_i values of 4.7 nM, 26 nM and 4000 nM, respectively. Nomifensine has antidepressant and analgesic effects. Nomifensine is used in neurodegenerative diseases, compound addiction, and pain research.

Nur für Forschungszwecke. Wir verkaufen nicht an Patienten.

Reinheit: 98.05%
CAS. Nr.: 24526-64-5
Formel: C₁₆H₁₈N₂
Molecular Weight:238.33

Speicherung:

Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 2 years , -20°C, 1 year

Nomifensine Chemical Structure

CAS. Nr.: 24526-64-5

Größe

Preis

Verfügbarkeit

Menge

Amount: USD 0.00

* Bitte wählen Sie Menge, bevor Sie Artikel hinzufügen.

Top Publications Citing

Use of MCE Products

Fluorescent Dye

Strong Fluorescence Signal / Multi-Disciplinary Applications / High Fluorescence Specificity

Biologische Aktivität
- Beschreibung
- Cellular Effect
- In Vivo
Chemical Information
Publications (6)
Lösungsmittel & Löslichkeit
- In Vitro
- In Vivo
Reinheit & Dokumentation
Verweise
Help & FAQs
Classifications
Bioz

Biologische Aktivität

Beschreibung

Alle Dopamine Receptor Isoform-spezifische Produkte anzeigen :

Alle Adrenergic Receptor Isoform-spezifische Produkte anzeigen :

Cellular Effect

Cell Line	Type	Value	Description	References
CHO-K1	IC₅₀	30.2 nM Compound: Nomifensine	Inhibition of [3H]dopamine reuptake at human DAT expressed in CHOK1 cells by scintillation counting Inhibition of [3H]dopamine reuptake at human DAT expressed in CHOK1 cells by scintillation counting	[PMID: 21093273]
CHO-K1	IC₅₀	>27 μM Compound: 3	Inhibition of human ERG expressed in CHO-K1 cells by electrophysiological assay Inhibition of human ERG expressed in CHO-K1 cells by electrophysiological assay	[PMID: 24900562]
Sf21	IC₅₀	>1000 μM Compound: Nomifensine	Inhibition of human BSEP expressed in plasma membrane vesicles of Sf21 cells assessed as inhibition of ATP-dependent [3H]taurocholate uptake Inhibition of human BSEP expressed in plasma membrane vesicles of Sf21 cells assessed as inhibition of ATP-dependent [3H]taurocholate uptake	[PMID: 21965623]
Sf21	IC₅₀	>1000 μM Compound: Nomifensine	Inhibition of Sprague-Dawley rat Bsep expressed in plasma membrane vesicles of Sf21 cells assessed as inhibition of ATP-dependent [3H]taurocholate uptake Inhibition of Sprague-Dawley rat Bsep expressed in plasma membrane vesicles of Sf21 cells assessed as inhibition of ATP-dependent [3H]taurocholate uptake	[PMID: 21965623]

In Vivo

Nomifensine (10 mg/kg; i.p.; 12 days) reduces response latency and increases activity in WKY rats, with no significant effect on Wistar rats^[3].
Nomifensine (5 mg/kg/day; s.c. using minipumps; 2-14 days) potently and significantly inhibits dopamine neuronal firing in the ventral tegmental area of SD rats after 2 days, with recovery to normal after 14-day treatment due to D₂ autoreceptor desensitization^[4].
Nomifensine (0.625-5 mg/kg; s.c.; 30 min before testing) produces analgesia (only in the formaldehyde test) and abolishs the nociceptive behavior induced by 2% formaldehyde in rats^[6].
Nomifensine (20 mg/kg; i.p.; once a day; 6 consecutive days) can suppress the neurotoxicity of MPTP (HY-15608) in C57 black mice, inhibiting the long-term depletion of neostriatal DA concentration induced by MPTP^[7].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:

Wistar Kyoto and Sprague-Dawley rats^[3]
Dosage:

10 mg/kg
Administration:

i.p.; once; for 12 days
Result:

Decreased the time Wistar Kyoto, but not Sprague-Dawley, rats spend immobile in the forced swim test.
Increased locomotor activity in the open field test in Wistar Kyoto and Sprague-Dawley rats.

Chemical Information

CAS. Nr. 24526-64-5
Appearance Solid
Molecular Weight 238.33
Formel C₁₆H₁₈N₂
Color Light yellow to yellow
SMILES

NC1=CC=CC2=C1CN(C)CC2C3=CC=CC=C3
Synonyms

(±)-Nomifensine; Nomifensin
Versand

Room temperature in continental US; may vary elsewhere.

Speicherung

Powder	-20°C	3 years
	4°C	2 years
In solvent	-80°C	2 years
	-20°C	1 year

Publications (6)

All

Sort by:

Journal Impact Factor

Commun Biol

A memory-driven auditory program ensures selective and precise vocal imitation in zebra finches. [Abstract]

2021 Sep 13;4(1):1065. PMID: 34518637
Glia

Downregulation of miR-7116-5p in microglia by MPP+ sensitizes TNF-α production to induce dopaminergic neuron damage. [Abstract]

2017 Aug;65(8):1251-1263. PMID: 28543680
Biotechnol Bioeng

An integrated biomimetic array chip for establishment of collagen-based 3D primary human hepatocyte model for prediction of clinical drug-induced liver injury. [Abstract]

2021 Dec;118(12):4687-4698. PMID: 34478150
Neurosci Lett

Learning from a novel "Tutor" Uncouples song imitation and preference in zebra finches. [Abstract]

2025 Oct 25:866:138373. PMID: 40912353
bioRxiv

2024 June 12.
bioRxiv

2023 Aug 3.

Lösungsmittel & Löslichkeit

In Vitro:

DMSO : ≥ 100 mg/mL (419.59 mM; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

* "≥" means soluble, but saturation unknown.

View the Complete Stock Solution Preparation Table

Preparing Stock Solutions

View the Complete Stock Solution Preparation Table

Concentration Solvent Mass

1 mg

5 mg

10 mg

Concentration

Solvent

Mass

1 mM

4.1959 mL

20.9793 mL

41.9586 mL

5 mM

0.8392 mL

4.1959 mL

8.3917 mL

10 mM

0.4196 mL

2.0979 mL

4.1959 mL

Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.

Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.

Molaritätsrechner

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass Mass

Konzentration Konzentration

Volumen Volumen

Molecular Weight Molecular Weight

Verdünnungsrechner

Konzentration _{(Stammlösung)} × Volumen _{(Stammlösung)} = Konzentration _{(Ziellösung)} × Volumen _{(Ziellösung)}

Konzentration _{(Stammlösung)} Konzentration _{(Stammlösung)}

Volumen _{(Stammlösung)} Volumen _{(Stammlösung)}

Konzentration _{(Ziellösung)} Konzentration _{(Ziellösung)}

Volumen _{(Ziellösung)} Volumen _{(Ziellösung)}

In Vivo:

Select the appropriate dissolution method based on your experimental animal and administration route.

Stock Solution Working Solution

For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

Protocol 1

Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline

Solubility: ≥ 2.5 mg/mL (10.49 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.

Protocol 2

Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)

Solubility: ≥ 2.5 mg/mL (10.49 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.

In Vivo Dissolution Calculator

Please enter the basic information of animal experiments:

Dosage Dosage
mg/kg
Animal Weight (Per Animal) Animal Weight (Per Animal)
g
Dosing Volume (Per Animal) Dosing Volume (Per Animal)
μL
Number of Animals Number of Animals

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Please enter your animal formula composition:

%
DMSO +

Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
%
+
+
%
Tween-80 + +
%
Saline +

The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).

Working solution concentration: 0.22 mg/mL

Reinheit & Dokumentation

Select Batch:

Reinheit: 99.98%

Assay: 99.98%

ee.: 99.98%

Data Sheet (278 KB)
SDS (480 KB)
- English - EN (480 KB)
- Français - FR (480 KB)
- Deutsch - DE (480 KB)
- Norwegian - NO (480 KB)
- Español - ES (480 KB)
- Swedish - SV (480 KB)
- Italian - IT (480 KB)
- Korean - KR (480 KB)
- Portuguese - PT (480 KB)
COA (2659 KB)
Elemental Analysis Report (2659 KB)
HNMR (2659 KB)
CNMR (2659 KB)
RP-HPLC (2659 KB)
NP-HPLC (2659 KB)
MS (2659 KB)
LCMS (2659 KB)
IR (2659 KB)
GC (2659 KB)
OR (2659 KB)
SDS-PAGE (2659 KB)
SEC-HPLC (2659 KB)
Other Report (2659 KB)
Handling Instructions (2659 KB)

Verweise

[1]. Hyttel J, et al. Neurochemical profile of Lu 19-005, a potent inhibitor of uptake of dopamine, noradrenaline, and serotonin. J Neurochem. 1985 May;44(5):1615-22. [Content Brief]

[2]. Tuomisto J. Nomifensine and its derivatives as possible tools for studying amine uptake. Eur J Pharmacol. 1977 Mar 21;42(2):101-6. [Content Brief]

[3]. Tejani-Butt S, et al. Strain-dependent modification of behavior following antidepressant treatment. Prog Neuropsychopharmacol Biol Psychiatry. 2003 Feb;27(1):7-14. [Content Brief]

[4]. Katz NS, et al. Effects of acute and sustained administration of the catecholamine reuptake inhibitor nomifensine on the firing activity of monoaminergic neurons. J Psychopharmacol. 2010 Aug;24(8):1223-35. [Content Brief]

[5]. Kang SH, et al. Transformation of nomifensine using ionizing radiation and exploration of its anticancer effects in MCF-7 cells. Exp Ther Med. 2022 Apr;23(4):306. [Content Brief]

[6]. Gilbert AK, et al. Characterization of the analgesic properties of nomifensine in rats. Pharmacol Biochem Behav. 2001 Apr;68(4):783-7. [Content Brief]

[7]. Melamed E, et al. Suppression of MPTP-induced dopaminergic neurotoxicity in mice by nomifensine and L-DOPA. Brain Res. 1985 Sep 9;342(2):401-4. [Content Brief]

Help & FAQs

How should lyophilized recombinant proteins be reconstituted and stored?

1. Before opening the cap, centrifuge the vial at 13000 rpm for 20-30 seconds. This step will ensure that any lyophilized powder that may have adhered to the cap or walls is collected at the bottom of the vial, minimizing the risk of product loss.

Complete Stock Solution Preparation Table

Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.

Optional Solvent	Concentration Solvent Mass	1 mg	5 mg	10 mg	25 mg
DMSO	1 mM	4.1959 mL	20.9793 mL	41.9586 mL	104.8966 mL
	5 mM	0.8392 mL	4.1959 mL	8.3917 mL	20.9793 mL
	10 mM	0.4196 mL	2.0979 mL	4.1959 mL	10.4897 mL
	15 mM	0.2797 mL	1.3986 mL	2.7972 mL	6.9931 mL
	20 mM	0.2098 mL	1.0490 mL	2.0979 mL	5.2448 mL
	25 mM	0.1678 mL	0.8392 mL	1.6783 mL	4.1959 mL
	30 mM	0.1399 mL	0.6993 mL	1.3986 mL	3.4966 mL
	40 mM	0.1049 mL	0.5245 mL	1.0490 mL	2.6224 mL
	50 mM	0.0839 mL	0.4196 mL	0.8392 mL	2.0979 mL
	60 mM	0.0699 mL	0.3497 mL	0.6993 mL	1.7483 mL
	80 mM	0.0524 mL	0.2622 mL	0.5245 mL	1.3112 mL
	100 mM	0.0420 mL	0.2098 mL	0.4196 mL	1.0490 mL

Keywords

Nomifensine

6 Cited Publications

100 mg Angebot einholen

Subscribe to the

MedChemExpress

Newsletter

Produktname:
Art. -Nr.:
Menge:
MCE Japan Authorized Agent:

Produktname:
CAS. Nr.:
Species:
Reinheit:
Menge:

Nomifensine

GPCR/G Protein Compound Library

Neuronal Signaling Compound Library

FDA-Approved Drug Library

Drug Repurposing Compound Library

Neurotransmitter Receptor Compound Library

FDA Approved & Pharmacopeial Drug Library

Anti-Alzheimer's Disease Compound Library

Drug-Induced Liver Injury (DILI) Compound Library

Neurodegenerative Disease-related Compound Library

Antidepressant Compound Library

Human Metabolite Library

Coagulation and Anti-coagulation Compound Library

Withdrawn Drug Compound Library

Off-patent Drug Library

Antihypertensive Compound Library

Membrane Protein-targeted Compound Library

Membrane Receptor-targeted Compound Library

Dopamine Receptor Compound Library

Multi-Target Compound Library

Bioactive Compound Library Max

MCE Bioactive Compound Library

Drug Repurposing Compound Library Plus

FDA-Approved Drug Library Plus

FDA-Approved Drug Library Mini

Bioactive Compound Library

High-Throughput Bioactive Compound Library

Mass Spectrometry Human Metabolite Library

Lactylation Compound Library

3D Diverse Fragment Library

Drug Fragment Library

Publications Citing Use of MedChemExpress (MCE) Nomifensine

Alle Dopamine Receptor Isoform-spezifische Produkte anzeigen

Alle Adrenergic Receptor Isoform-spezifische Produkte anzeigen

Biologische Aktivität

Chemical Information

Publications (6)

Lösungsmittel & Löslichkeit

Reinheit & Dokumentation

Verweise

Help & FAQs

Complete Stock Solution Preparation Table

Nomifensine Related Classifications

HY-B1110 Related Classifications